AU2006314226B2 - Therapeutic uses of steroidal compounds - Google Patents

Therapeutic uses of steroidal compounds Download PDF

Info

Publication number
AU2006314226B2
AU2006314226B2 AU2006314226A AU2006314226A AU2006314226B2 AU 2006314226 B2 AU2006314226 B2 AU 2006314226B2 AU 2006314226 A AU2006314226 A AU 2006314226A AU 2006314226 A AU2006314226 A AU 2006314226A AU 2006314226 B2 AU2006314226 B2 AU 2006314226B2
Authority
AU
Australia
Prior art keywords
pain
neuropathic pain
nerve
galanin
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006314226A
Other languages
English (en)
Other versions
AU2006314226A1 (en
Inventor
James Robert Murray
Ernst Wulfert
David Wynick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hunter Fleming Ltd
Original Assignee
Hunter Fleming Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunter Fleming Ltd filed Critical Hunter Fleming Ltd
Publication of AU2006314226A1 publication Critical patent/AU2006314226A1/en
Application granted granted Critical
Publication of AU2006314226B2 publication Critical patent/AU2006314226B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2006314226A 2005-11-18 2006-11-17 Therapeutic uses of steroidal compounds Ceased AU2006314226B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0523550.2 2005-11-18
GBGB0523550.2A GB0523550D0 (en) 2005-11-18 2005-11-18 Therapeutic uses of steroidal compounds
PCT/GB2006/004305 WO2007057691A2 (en) 2005-11-18 2006-11-17 Therapeutic uses of steroidal compounds

Publications (2)

Publication Number Publication Date
AU2006314226A1 AU2006314226A1 (en) 2007-05-24
AU2006314226B2 true AU2006314226B2 (en) 2012-02-02

Family

ID=35580318

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006314226A Ceased AU2006314226B2 (en) 2005-11-18 2006-11-17 Therapeutic uses of steroidal compounds

Country Status (16)

Country Link
US (1) US8846652B2 (https=)
EP (1) EP1948192A2 (https=)
JP (1) JP5395437B2 (https=)
KR (1) KR101314694B1 (https=)
CN (1) CN101346144B (https=)
AU (1) AU2006314226B2 (https=)
CA (1) CA2630441C (https=)
GB (1) GB0523550D0 (https=)
IL (1) IL191457A (https=)
MX (1) MX2008006440A (https=)
NO (1) NO20082741L (https=)
NZ (1) NZ568560A (https=)
RU (1) RU2427375C2 (https=)
TW (1) TWI386211B (https=)
WO (1) WO2007057691A2 (https=)
ZA (1) ZA200804266B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20110244A7 (es) 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
CN108434090A (zh) * 2017-02-14 2018-08-24 高药品股份有限公司 以生理脂肪为基剂的类固醇药膏
RU2745868C9 (ru) * 2020-05-28 2021-04-08 Федеральное государственное бюджетное образовательное учреждение высшего образования «Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва» Способ ускорения регенерационных процессов в поврежденных периферических нервах

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565444A (en) * 1993-05-18 1996-10-15 Ltt Institute Co., Ltd. Osteogenesis promoter and osteoporosis remedy
WO2002072084A2 (en) * 2001-03-08 2002-09-19 Sterix Limited Glycyrrhetinic acid derivatives, progesterone and progesterone derivatives and their use for the manufacture of a medicament to inhibit 11beta-hydroxysteroid dehydrogenase activity
WO2005105104A1 (en) * 2004-04-28 2005-11-10 Hunter-Fleming Limited Transdermal steroid formulation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012997A1 (en) 1991-01-16 1992-08-06 The General Hospital Corporation Human galanin
WO1992015015A1 (en) 1991-02-25 1992-09-03 Zymogenetic, Inc. Methods for detecting galanin antagonists
DE69225706T2 (de) 1991-03-06 1998-11-26 Garvan Institute Of Medical Research, Darlinghurst, Neu Sued Wales/New South Wales Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen
SE9101472D0 (sv) 1991-05-15 1991-05-15 Trion Forskning & Utveckling Galanin antagonist
JPH06172387A (ja) 1992-12-11 1994-06-21 Aibaitsu Kk 合成ペプチド誘導体
JPH09151197A (ja) * 1995-11-29 1997-06-10 L T T Kenkyusho:Kk 自己免疫疾患治療薬
DE69739760D1 (de) 1996-07-24 2010-03-25 Neurotargets Ltd Verwendung eines Galanin-agonisten in der Herstellung eines Medikaments zur Verbesserung des Gedächtnisses und anderer cognitiver Funktionen
JP2000169374A (ja) * 1998-12-03 2000-06-20 Ltt Kenkyusho:Kk Ｉｇｆ増強剤
TR200200406T2 (tr) * 1999-06-11 2002-06-21 Watson Pharmaceuticals, Inc. Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması
DE10054294A1 (de) * 2000-11-02 2002-05-16 Heinrich Wieland Topische Behandlung bei der Mastalgie
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
WO2002096934A1 (en) 2001-05-25 2002-12-05 Kemia, Inc. Non-natural galanin receptor ligands
DK1406606T3 (da) 2001-07-16 2007-03-05 Ortho Mcneil Pharm Inc Carbamatforbindelser til forebyggelse eller behandling af neuropatisk smerte og smerte forbundet med klynge- og migrænehovedpine
JP2004538305A (ja) 2001-07-31 2004-12-24 ファルマシア・アンド・アップジョン・カンパニー ３−ヘテロシクリル−及び３−シクロアルキル−３−アリールオキシプロパンアミンによる慢性疼痛の治療
WO2003011272A1 (en) 2001-07-31 2003-02-13 Pharmacia & Upjohn Company Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines
ATE332688T1 (de) 2001-10-16 2006-08-15 Endo Pharmaceuticals Inc Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
GB0403509D0 (en) 2004-02-17 2004-03-24 Neuro Targets Ltd Galanin receptors and brain injury
JP5449775B2 (ja) * 2005-10-19 2014-03-19 チャバフ ピーティーワイ エルティーディー 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減
WO2008065408A2 (en) 2006-11-30 2008-06-05 Hunter-Fleming Limited Modulation of prostaglandin/cyclooxygenase metabolic pathways

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565444A (en) * 1993-05-18 1996-10-15 Ltt Institute Co., Ltd. Osteogenesis promoter and osteoporosis remedy
WO2002072084A2 (en) * 2001-03-08 2002-09-19 Sterix Limited Glycyrrhetinic acid derivatives, progesterone and progesterone derivatives and their use for the manufacture of a medicament to inhibit 11beta-hydroxysteroid dehydrogenase activity
WO2005105104A1 (en) * 2004-04-28 2005-11-10 Hunter-Fleming Limited Transdermal steroid formulation

Also Published As

Publication number Publication date
US8846652B2 (en) 2014-09-30
MX2008006440A (es) 2008-12-01
RU2008124834A (ru) 2009-12-27
JP5395437B2 (ja) 2014-01-22
WO2007057691A2 (en) 2007-05-24
TW200730180A (en) 2007-08-16
NZ568560A (en) 2010-11-26
CN101346144A (zh) 2009-01-14
IL191457A (en) 2013-10-31
AU2006314226A1 (en) 2007-05-24
WO2007057691A3 (en) 2007-08-02
CA2630441C (en) 2013-10-29
CN101346144B (zh) 2011-07-20
US20090227551A1 (en) 2009-09-10
ZA200804266B (en) 2009-01-28
CA2630441A1 (en) 2007-05-24
GB0523550D0 (en) 2005-12-28
JP2009515939A (ja) 2009-04-16
TWI386211B (zh) 2013-02-21
IL191457A0 (en) 2009-08-03
KR101314694B1 (ko) 2013-10-07
NO20082741L (no) 2008-07-23
KR20080073755A (ko) 2008-08-11
RU2427375C2 (ru) 2011-08-27
EP1948192A2 (en) 2008-07-30

Similar Documents

Publication Publication Date Title
CA2513717C (fr) Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
CN1612745A (zh) 延缓衰老以及治疗和预防衰老相关疾病的方法
Wang et al. Human breast milk-derived exosomes protect against intestinal ischemia and reperfusion injury in neonatal rats
Miyazato et al. Inhibitory effect of intrathecal glycine on the micturition reflex in normal and spinal cord injury rats
US20100152150A1 (en) The application of marine steroid in preparing the medicine of treating neurons damaging
Dazzi et al. Inhibition by the neurosteroid allopregnanolone of basal and stress-induced acetylcholine release in the brain of freely moving rats
Murck et al. Galanin has REM-sleep deprivation-like effects on the sleep EEG in healthy young men
EP3856187A1 (en) Infigratinib for treatment of fgfr3-related skeletal diseases during pregnancy
IL191457A (en) Use of the history of androstene – 17,3 – discussion for the preparation of the drug for the treatment of neuropathic pain
RU2346690C2 (ru) Применение прегнандионов или прегнандиолов в качестве невропатических анальгетических агентов
JP2010511028A5 (https=)
CN101594861B (zh) 前列腺素/环加氧酶代谢途径的调节
McNeil et al. Reversal of ethanol and indomethacin‐induced suppression of hepatic DNA synthesis by 16, 16‐dimethyl prostaglandin E2
JP2009515939A5 (https=)
JP4942905B2 (ja) 神経保護活性を有する７−ヒドロキシエピアンドロステロン
WO2008060949A2 (en) Compounds with anti-androgenic activity and the use thereof
WO2007123234A1 (ja) 抗てんかん作用増強剤
JPH05208916A (ja) Ｇｍ１ガングリオシドのメチルエステルの抗ニューロン毒活性およびその治療のための使用
EP1490069B1 (en) Alpha aed and beta aed regulation of nuclear transcription, gene regulation, and/or gene expression
CN104436166A (zh) 神经生长因子在制备治疗脊髓损伤药物中的应用
HK40060507B (zh) 包含环（组氨酸-脯氨酸）二肽及甲状旁腺激素的组合物用於预防、改善或治疗骨质流失疾病的用途
Reddy Neurosteroid influences on neuronal excitability: the menstrual cycle and catamenial epilepsy as dynamic models
SE514606C2 (sv) Läkemedel innehållande GnRH-analoger för behandling av schizofreni
HK1077738A (en) Methods for slowing senescence and treating and preventing diseases associated with senescence

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired